Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 December 2021 | Story André Damons | Photo Charl Devenish
Prof Felicity Burt, expert in arbovirology in the Division of Virology at the University of the Free State (UFS) and the National Health Laboratory Service (NHLS).

Even though not much is yet known about the new COVID-19 variant, Omicron, the presence of a high number of mutations – more than 30 – in the spike protein of the variant raises concern. 

This is according to Prof Felicity Burt, expert in arbovirology in the Division of Virology at the University of the Free State (UFS) and the National Health Laboratory Service (NHLS). According to her, although Omicron is highly transmissible, further epidemiological data is required to determine if it is more transmissible than the Delta variant.

On Friday 26 November, the World Health Organisation (WHO) declared the new variant, B.1.1.529, a variant of concern (VOC) and assigned it the name Omicron. This assignation was based on advice from the Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE), an independent group of experts responsible for monitoring and evaluating emerging variants. The following are considered when categorising a newly identified variant – are there mutations (changes in the viral genes) that are known, or that have the potential, to affect the characteristics of the virus, such as transmissibility, disease severity, immune escape, diagnostic or therapeutic escape; is there significant community transmission or increasing prevalence in multiple countries over time; are the public health and social measures effective against the variant.

With each new variant, the public health concerns are dependent on the transmissibility of the variant, the ability of the virus to escape immunity from natural infection or from vaccination, and the severity of illness caused by the variant or any change in clinical presentation. In addition, the ability of current diagnostic assays to adequately detect the variant and effectiveness of public health and social measures, must be considered.

We know, we don’t know 

Answers are derived from existing epidemiological data, laboratory research, and theoretical considerations. Although we can make some predictions based on the mutations identified and the location of these mutations, the epidemiological data and laboratory research are essential to answer with certainty, and this can take some time. The presence of a high number of mutations – more than 30 – in the spike protein of Omicron, raises concern. What do we know and what don’t we know?

“What we don’t know is whether these mutations have changed the severity of disease caused by the virus. We do know that the diagnostic PCR tests currently used in South Africa are not compromised by the presence of these mutations, and in fact, one of the molecular assays commonly used to target three regions of the virus, can be used as a rapid biomarker to detect the variant. Although sequencing of the genome is used as confirmation, this assay provides a useful rapid biomarker that can be used to detect the presence of the variant; subsequently, PCR results have shown that the variant is likely already present in most provinces in the country,” says Prof Burt, who currently holds an NRF-DST South African Research Chair in vector-borne and zoonotic pathogens research. 

There is also preliminary epidemiological evidence that reinfections are occurring. According to her, the occurrence of reinfections suggests some degree of immune escape; however, we do not know the extent of immune escape or the contribution of waning immunity towards reinfections. “Laboratory tests, in which the live virus is tested against samples from both recovered and vaccinated people, are required to confirm whether existing antibodies can neutralise the variant. The tests for neutralising antibodies require specialised facilities and is dependent on culturing the virus. 
“These tests are already underway in the country and should provide more information in the coming weeks. 

Neutralising antibody tests, although time consuming, are relatively easy to perform compared to tests to determine the role played by other arms of the immune response.”

Vaccines still best option to fight COVID-19

Prof Burt, who has worked on viral haemorrhagic fevers and arboviruses at the National Institute for Communicable Diseases (NICD), says it is known that vaccines are highly effective in reducing the severity of disease and fatalities in individuals infected with other variants, such as Beta and Delta, despite mutations in critical regions of the spike gene in the variants. 

The epidemiological data acquired from cases and the results of laboratory tests for neutralising capability will contribute towards understanding the effectiveness of the vaccine against Omicron. The questions regarding severity of the disease and level of protection from previous infection and vaccines are priority areas to understand the impact of this variant. The early identification of the variant and the initiation of vital research and data analysis highlight the importance of genomic surveillance.

Cases of Omicron have already been confirmed in Israel, the United Kingdom, Europe, Australia, and Africa. Travel restrictions have previously been shown to be ineffective in stopping the geographical spread of new variants, merely delaying the inevitable, and at significant cost to economies. “We know with certainty that vaccination has reduced the severity of illness and death with previous variants; even in the face of reduced neutralising ability, there was sufficient protection to save lives,” says Prof Burt.  

She concluded, “Globally, the impact of vaccination is evident in countries experiencing fourth waves, with a reduced number of deaths compared to previous waves. Many decisions in life are based on a risk assessment and consideration of the pros and cons. Vaccines save lives. Vaccines definitely boost waning immune responses from natural infection.” 

“This is certainly not the time to reject the vaccine based on perceived risks from inaccurate social media spreading harmful disinformation compared to the known risks associated with contracting COVID-19 and the known protection against severe disease afforded by the vaccines.”

News Archive

Alexander Ramm Cello Recital with Pieter Jacobs (piano)
2016-04-15

Description: Ramm Tags: Ramm

Alexander Ramm

“Ramm plays with enormous musical authority. Unlike many young instrumentalists, he is not intimidated by the reflective or the elegiac; nor is he nervous about the length of pauses, or the creation of inter-phrase silence. He has a phenomenal technique and he demonstrated it to full effect in this captivating performance.” (Cape Times)

Alexander Ramm belongs to the new generation of cellists recognised for his appealing artistic creativity and unprecedented technical skills. Alexander started his musical education at the age of seven at the Glier music school (Kaliningrad) with Svetlana Ivanova. Her extremely serious attitude to music studies and pedagogical talent revealed the rare musical capabilities of this young cellist.

After moving to Moscow at the age of ten, he was accepted to the class of Maria Zhuravleva at the Chopin Moscow College of Music Performance. From 2007, he continued his professional education at the Moscow Conservatory in the class of the renowned musician and the People’s Artist of the USSR, Natalia Shakhovskaya, an outstanding performer and pedagogue who taught most prominent Russian cellists. Since 2012, he has become a postgraduate student at the Hanns-Eisler Hochschule fur Musik under the guidance of the famous cellist, Frans Helmerson.

From the age of nine, when he made his debut as a soloist with the Kaliningrad Chamber Orchestra, Alexander brilliantly performs with solo programmes and as a soloist with leading orchestras in Russia and worldwide.

He is prizewinner at several international competitions:
1st prize: 4th Moscow Competition for young cellists (2003)
1st prize: 1st Cambridge International Boston Competition (Massachusetts, 2005)
Grand-Prix: Moscow Festival of Romantic Music (Moscow, 2006)
4th prize: 5th UNISA International String Competition (South Africa, 2010)
1st prize: 3rd Beijing International Music Competition (Beijing 2010)
1st prize: 1st All-Russia Music Competition (Russia, 2010)
Prizewinner: Janigro Cello Competition (Croatia, 2012)
Prizewinners: Swedish Duo Competition with duo partner Anna Odintsova (2012)
3rd prize: Paulo Cello Competition (2013) – becoming the first Russian prizewinner in the history of this prestigious contest
2nd prize: XV International Tchaikovsky Competition (2015)

Alexander participated in masterclass festivals at Courchevel Academy and Holland Music Sessions, where he took lessons from the famous musicians such as F. Muller, R. Latzko, M. Kliegel and U. Wiesel. In 2011, he took part in the well-known Verbier festival, where he studied with H. Hoffmann, F. Helmerson, M. Suzuki, L. Power and F. Radosh. At the end of the festival, he was awarded the Neva Foundation top-level prize for gifted students.

Alexander cooperates with such outstanding conductors as V. Gergiev, V. Spivakov, A. Levin, K. Orbelyan, V. Polyansky, S. Kochanovsky, M. Fedotov, A. Slutsky, A. Sladkovsky.

He will be accompanied by Pieter Jacobs, a graduate of the University of Pretoria, who then furthered his studies at Yale in the United States, where he pursued his performing career with considerable success as a soloist and chamber musician in Boston, Cambridge and New Haven before returning to South Africa to perform and teach at the University of Pretoria. Pieter is regarded as one of SA’s foremost pianists and chamber musicians.

Programme:

Grieg: Cello Sonata, Op. 36 in A minor (1883)
Barber: Cello Sonata, Op. 6 in C minor (1932)
Prokofiev: Cello Sonata, Op. 119 (1949)
Piazzolla: Le Grand Tango for cello and piano

Date: 22 April 2016
Time: 19:30
Venue: Odeion
Costs: R130 (adults), R90 (pensioners), R70 (UFS staff members), R50 (students and learners), R50 (group booking of 10+). Tickets available at Computicket.

More information: Ninette Pretorius +27(0)51 401 2504.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept